Pharmacokinetics of once-daily darunavir/ ritonavir with and without etravirine in human immunodeficiency virus-infected children, adolescents, and young adults

for the International Maternal Pediatric and Adolescent AIDS Clinical Trial Protocol P1058A Team

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Limited data are available for once-daily (QD) darunavir (DRV)/ritonavir (r) in the pediatric population. Coadministration of etravirine (ETR) may alter the pharmacokinetics (PK) of DRV. We evaluated the PK interactions between DRV/r (QD) and ETR QD or twice-daily (BID) in children, adolescents, and young adults. Methods. Human immunodeficiency virus-infected subjects 9 to < 24 years old on optimized background therapy including DRV/r 800/100 mg QD alone or combined with ETR 200 mg BID or ETR 400 mg QD were enrolled. Protocol-defined target drug exposure ranges based on adult data were used to assess the adequacy of each regimen. Intensive 24-hour blood sampling was performed, and PK parameters were determined using noncompartmental analysis. Results. Thirty-one subjects (14 males) completed the study; 16 received DRV/r QD alone (group 1), 6 received DRV/r plus ETR BID (group 2A), and 9 received DRV/r plus ETR QD (group 2B). The geometric mean (90% confidence interval [CI] geometric mean) for DRV area under the curve at 24 hours (AUC24) was 57.9 (49.6-67.6), 74.9 (44.4-126.5), and 66.4 (50.8-86.9) mg × h/L for patients in groups 1, 2A, and 2B, respectively. The increased DRV exposure when coadministered with ETR was not statistically significant. The geometric mean (90% CI geometric mean) of ETR AUC24 was 8.6 (4.4-16.8) and 11.9 (7.5-18.9) mg × h/L for groups 2A and 2B, respectively, with comparable C24. Conclusions. The results suggest that DRV/r QD with ETR 400 mg QD or 200 mg BID is appropriate and support further evaluation of the safety and efficacy of the once-daily regimen in older children, adolescents, and young adults.

Original languageEnglish (US)
Pages (from-to)131-137
Number of pages7
JournalJournal of the Pediatric Infectious Diseases Society
Volume5
Issue number2
DOIs
StatePublished - Jun 10 2016

Keywords

  • Antiretrovirals
  • Darunavir
  • Etravirine
  • Pediatrics
  • Pharmacokinetics
  • Ritonavir

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Pharmacokinetics of once-daily darunavir/ ritonavir with and without etravirine in human immunodeficiency virus-infected children, adolescents, and young adults'. Together they form a unique fingerprint.

Cite this